First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors
Rom S. Leidner(Providence Portland Medical Center), John A. Thompson(Fred Hutch Cancer Center)
Cited by 23
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
|New England Journal of Medicine|2008|903
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
|Journal of the National Comprehensive Cancer Network|2019|116